Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation

PharmacoEconomics

Volumn 32, Issue 6, 2014, Pages 601-612

  Wisløff, Torbjørn ^a,b,c   Hagen, Gunhild ^a,d   Klemp, Marianne ^a,c  

^a NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THIOPHENE DERIVATIVE;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; ECONOMIC EVALUATION; FEMALE; GROUPS BY AGE; HEALTH STATUS; HEART ATRIUM FIBRILLATION; HEART FAILURE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; COMPLICATION; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; NORWAY; PROBABILITY; RISK FACTOR; STATISTICAL MODEL; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; MARKOV CHAINS; MODELS, STATISTICAL; MORPHOLINES; NORWAY; PYRAZOLES; PYRIDONES; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; STROKE; THIOPHENES; WARFARIN;

EID: 84902242738     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0152-z     Document Type: Article

References (58)

1. Friberg J, Scharling H, Gadsboll N, Truelsen T, Jensen GB. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol. 2004;94(7):889-94. (Pubitemid 39359174)
2. Camm AJ, Lip GY, De CR, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation - developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14(10):1385-413.
3. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2-220.
4. Rivero-Ayerza M, Scholte Op RW, Lenzen M, Theuns DA, Jordaens L, Komajda M, et al. New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey. Eur Heart J. 2008;29(13):1618-24. (Pubitemid 351957546)
5. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):546S-92S.
6. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-429.
7. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: anti-thrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e531S-75S.
8. Limone BL, Baker WL, Kluger J, Coleman CI. Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. PLoS One. 2013;8(4):e62183.
9. Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices - overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making. 2012;32(5):667-77.
10. Coyle D, Coyle K, Cameron C, Lee K, Kelly S, Steiner S, et al. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health. 2013;16(4):498-506.
11. Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke. 2013;44(6):1676-81.
12. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137(2):263-72.
13. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-100.
14. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study. Eur Heart J. 2012;33(12):1500-10.
15. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.
16. Harmsen P, Wilhelmsen L, Jacobsson A. Stroke incidence and mortality rates 1987 to 2006 related to secular trends of cardiovascular risk factors in Gothenburg, Sweden. Stroke. 2009;40(8):2691-7.
17. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433-41.
18. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost. 2011;106(4):739-49.
19. Øyen N, Nygård O, Igland J, Tell GS, Nordrehaug JE, Irgens LM, et al. Hospital admission rates for cardiovascular diseases in Western Norway, 1992-2001 [in Norwegian]. Tidsskr Nor Laegeforen. 2008;128(1):17-23.
20. Henriksson KM, Farahmand B, Johansson S, Asberg S, Terent A, Edvardsson N. Survival after stroke - the impact of CHADS2 score and atrial fibrillation. Int J Cardiol. 2010;141(1):18-23.
21. Shafazand M, Rosengren A, Lappas G, Swedberg K, Schaufelberger M. Decreasing trends in the incidence of heart failure after acute myocardial infarction from 1993-2004: a study of 175,216 patients with a first acute myocardial infarction in Sweden. Eur J Heart Fail. 2011;13(2):135-41.
22. Tveit A, Flonaes B, Aaser E, Korneliussen K, Froland G, Gullestad L, et al. No impact of atrial fibrillation on mortality risk in optimally treated heart failure patients. Clin Cardiol. 2011;34(9):537-42.
23. Riks-Stroke. Yearly report 2010 [in Swedish]. http://www.riks-stroke.org/ content/analyser/Riks-Stroke-%C3%85rsrapport2010.pdf (2011). Accessed 22 Mar 2014.
24. Olesen JB, Lip GY, Hansen PR, Lindhardsen J, Ahlehoff O, Andersson C, et al. Bleeding risk in 'real world' patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost. 2011;9(8):1460-7.
25. Goto S, Bhatt DL, Rother J, Alberts M, Hill MD, Ikeda Y et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 2008;156(5):855-63, 863.e2.
26. Hillen T, Coshall C, Tilling K, Rudd AG, McGovern R, Wolfe CD. Cause of stroke recurrence is multifactorial: patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register. Stroke. 2003;34(6):1457-63. (Pubitemid 36693517)
27. Caro JJ, Migliaccio-Walle K, Ishak KJ, Proskorovsky I, O'Brien JA. The time course of subsequent hospitalizations and associated costs in survivors of an ischemic stroke in Canada. BMC Health Serv Res. 2006;6:99.
28. Mosterd A, Cost B, Hoes AW, de Bruijne MC, Deckers JW, Hofman A, et al. The prognosis of heart failure in the general population: the Rotterdam Study. Eur Heart J. 2001;22(15):1318-27. (Pubitemid 32737624)
29. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24(5):442-63. (Pubitemid 36286187)
30. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107(3):584-9.
31. Henriksson KM, Andersson T, Magnusson A, Bryngelsson I-L, Frobert O, Edvardsson N, et al. A cohort study of all-cause mortality in all patients with a first time hospitalization with atrial fibrillation, versus matched controls, In Sweden during 15 years, 1995-2009 [conference abstract]. Pharmacoepidemiol Drug Saf. 2011;20:S22-3.
32. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51.
33. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91.
34. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92.
35. Oxman AD. Subgroup analyses. BMJ. 2012;344:e2022.
36. European Medicines Agency. EPAR summary for the public: pradaxa, dabigatran etexilate (EMA/544606/2012). http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR---Summary-for-the-public/human/000829/WC500041060.pdf. (2012). Accessed 22 Mar 2014.
37. Norwegian Medicines Agency. Reimbursement report: dabigatran (Pradaxa) for prevention of stroke and systemic embolism [in Norwegian]. http://www.legemiddelverket.no/Blaa-resept-og-pris/blaaresept-forhaandsgodkjent- refusjon/refusjonsbeslutninger/Documents/2012-2011/Pradaxa-atrieflimmer-2012. pdf (2012). Accessed 22 Mar 2014.
38. Wisløff T, Selmer R, Halvorsen S, Kristiansen IS. Norwegian Cardiovascular Disease Model (NorCaD) - a simulation model for estimating health benefits and cost consequences of cardiovascular interventions. 23. 2008. Report from Kunnskapssenteret (Norwegian Knowledge Centre for the Health Services), No. 23-2008. http://www.kunnskapssenteret.no/publikasjoner/- attachment/4128?-ts=11d1a7a8760&download=false. Accessed 22 Mar 2014.
39. The Norwegian Directorate of Health. Economic evaluation of health interventions - a guideline [in Norwegian]. http://www.helsedirektoratet.no/ publikasjoner/okonomisk-evaluering-av-heletiltak-en-veileder/Publikasjoner/ IS-1985.pdf (2012 IS-1985). Accessed 22 Mar 2014.
40. Lunde L. Economic evaluations in the health care market: methodological issues and challenges [PhD thesis]. Bergen: University of Bergen; 2012.
41. Berg J, Lindgren P, Nieuwlaat R, Bouin O, Crijns H. Factors determining utility measured with the EQ-5D in patients with atrial fibrillation. Qual Life Res. 2010;19(3):381-90.
42. Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess. 2007;11(51): iii-iv, 1-164.
43. Lee HY, Hwang JS, Jeng JS, Wang JD. Quality-adjusted life expectancy (QALE) and loss of QALE for patients with ischemic stroke and intracerebral hemorrhage: a 13-year follow-up. Stroke. 2010;41(4):739-44.
44. Coleman CI, Sobieraj DM, Winkler S, Cutting P, Mediouni M, Alikhanov S, et al. Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. Int J Clin Pract. 2012;66(1):53-63.
45. Rasanen P, Roine E, Sintonen H, Semberg-Konttinen V, Ryynanen OP, Roine R. Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review. Int J Technol Assess Health Care. 2006;22(2):235-41.
46. Wisløff T, Hagen G, Hamidi V, Movik E, Klemp M, Olsen JA. Estimating QALY gains in applied studies: a review of cost-utility analyses published in 2010. Pharmacoeconomics. Epub 2014 Jan 30. doi:10.1007/s40273-014- 0136-z.
47. Briggs AH, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
48. Altman DG. Practical statistics for medical research. 1st ed. London: Chapman & Hall; 1991.
49. Thompson SG, Nixon RM. How sensitive are cost-effectiveness analyses to choice of parametric distributions? Med Decis Making. 2005;25(4):416-23. (Pubitemid 41023168)
50. Briggs AH, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
51. Lainscak M, Cleland JG, Lenzen MJ, Keber I, Goode K, Follath F, et al. Nonpharmacologic measures and drug compliance in patients with heart failure: data from the EuroHeart Failure Survey. Am J Cardiol. 2007;99(6B):31D-7D.
52. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10(8):779-87. (Pubitemid 34041389)
53. Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 2005;14(4):339-47. (Pubitemid 40514748)
54. Al MJ. Cost-effectiveness acceptability curves revisited. Pharmacoeconomics. 2013;31(2):93-100.
55. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003;6(1):9-17. (Pubitemid 36228345)
56. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975-83.
57. Graff-Iversen S, Gjesdal K, Jugessur A, Myrstad M, Nystad W, Selmer R, et al. Atrial fibrillation, physical activity and endurance training [in English, Norwegian]. Tidsskr Nor Laegeforen. 2012;132(3):295-9.
58. Wisløff T, Ringerike T, Hagen G, Reikvam Å, Klemp M. Efficacy and cost-effectiveness of new oral anticoagulants compared to warfarin for the prevention of stroke in patients with atrial fibrillation. 2013;5:1-79. http://www.kunnskapssenteret.no/Publikasjoner/-attachment/18119?-ts= 13df823146a&download=true. Accessed 22 Mar 2014.